Skye Bioscience director granted 75,000 stock options

Skye Bioscience director Annalisa Jenkins received a new stock option grant covering 75,000 shares of Common Stock.

Rhea-AI Filing Summary

Skye Bioscience director Annalisa Jenkins received a new stock option grant covering 75,000 shares of Common Stock. The option has an exercise price of $0.615 per share and expires on March 31, 2036. It vests in equal monthly installments over one year beginning March 31, 2026.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Jenkins Annalisa

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	75,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 75,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.

Key Figures

Option grant size: 75,000 shares Exercise price: $0.615 per share Options held after grant: 75,000 options +2 more

5 metrics

Option grant size 75,000 shares Underlying Common Stock in new stock option award

Exercise price $0.615 per share Stock option strike price for the 75,000-share grant

Options held after grant 75,000 options Total derivative securities following this transaction

Expiration date March 31, 2036 Stock option expiration for the 75,000-share award

Vesting schedule length 1 year Equal monthly vesting beginning March 31, 2026

Key Terms

Stock Option (Right to Buy), Common Stock, vests in equal monthly installments, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vests in equal monthly installments financial

"The stock option vests in equal monthly installments over the one year period"

exercise price financial

"conversion_or_exercise_price: 0.6150"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Skye Bioscience (SKYE) report for Annalisa Jenkins?

Skye Bioscience reported that director Annalisa Jenkins received a stock option grant for 75,000 shares of Common Stock. The option was awarded as compensation and gives her the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the new Skye Bioscience (SKYE) stock options?

The granted stock options have an exercise price of $0.615 per share. This means Jenkins can later purchase up to 75,000 Skye Bioscience common shares at $0.615, regardless of the market price at the time of exercise.

How do the Skye Bioscience (SKYE) options granted to Annalisa Jenkins vest?

The stock option vests in equal monthly installments over one year starting March 31, 2026. Each month, a portion of the 75,000 underlying shares becomes exercisable, aligning her compensation with continued board service during that 12‑month period.

When do the new Skye Bioscience (SKYE) stock options granted to Jenkins expire?

The stock option expires on March 31, 2036. After this expiration date, any unexercised portion of the 75,000-share grant can no longer be used to purchase Skye Bioscience common stock at the $0.615 exercise price.

Is the Skye Bioscience (SKYE) option grant to Annalisa Jenkins an open-market share purchase?

No, the transaction is a grant of a stock option, not an open‑market purchase. It was awarded as compensation, giving Jenkins the right to acquire 75,000 shares at $0.615 in the future as the option vests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 06:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jenkins Annalisa

(Last) (First) (Middle)

11250 EL CAMINO REAL

SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.615	03/31/2026		A		75,000		(1)	03/31/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.

Remarks:

	/s/ Punit S. Dhillon, as Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)